Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Ionis completed enrollment in the pivotal cohort of its Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome, randomizing 136 pediatric participants aged 2 to 18. Topline data from the study is anticipated in the second half of 2027, while the company expects to complete enrollment in an adult cohort by the third quarter of 2026.
Key figures
- Drug Name
- obudanersen (ION582)
- Phase Of Trial
- Phase 3
- Cohort 1 age range
- 2 to < 18 years old
- Cohort 2 age range
- 18 to ≤ 50 years old
- Total study enrollment
- 158
- Pivotal cohort enrollment
- 136
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.